HLF-positive B cell acute lymphoblastic leukemia (B-ALL) sits among the most aggressive blood cancers seen in children. The ...

Myeloma delivery constraints are dominated by CAR T infrastructure and onboarding, while bispecifics are more community-feasible after induction; sequencing may favor CAR T first to preserve T-cell ...

AML induction shifts beyond 7+3 as venetoclax, hypomethylating agents, and FLT3 inhibitors drive less toxic combos and oral options. In an interview with Targeted Oncology, Richard Stone, MD, ...

Yatiri used its AI-based proteomics and functional testing platform to identify a biomarker profile for best responders to denfivontinib.

Yatiri Bio, Inc., a leader in AI-driven precision medicine, today announced it has entered into an exclusive global option to license agreement with Oscotec, Inc. to develop and commercialize ...

Oncotelic Therapeutics, Inc. (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”), a leader in RNA-based therapeutics, announced today that its subsidiary Sapu Nano will formally introduce its ...

A heartfelt appeal from a woman who desperately needs £100,000 funding for a stem cell transplant was answered by an ...

HLF-positive B cell acute lymphoblastic leukemia (B-ALL) sits among the most aggressive blood cancers seen in ...

Mumbai: Narayana Health SRCC Children’s Hospital, Mumbai, has successfully treated 12-year-old Pradeep Kumar (patient), who was battling a rare and aggressive progressive leukemia. The ...

Patients testing positive for NPM1 MRD pre-alloHCT have significantly increased rates of relapse, reduced overall survival ...

ASH convened a multidisciplinary panel to develop evidence-based guidelines for the treatment of newly diagnosed acute myeloid leukemia in older adults, focusing on balancing treatment efficacy with ...